Grifols (GIKLY) Common Equity (2010 - 2025)
Grifols (GIKLY) reported Common Equity of $8.9 billion for Q4 2025, down 3.76% on a YoY basis from $9.2 billion in Q4 2024, and down 3.76% quarter-over-quarter from $9.2 billion in Q4 2024.
Grifols (GIKLY) Common Equity (2010 - 2025) Analysis & Trends
Grifols has reported Common Equity for 16 years, with the latest figure at $8.9 billion in Q4 2025.
- For the quarter ending Q4 2025, Common Equity fell 3.76% year-over-year to $8.9 billion; the trailing twelve-month figure through Dec 2025 stood at $8.9 billion (down 3.76% YoY), and the FY2025 full-year result was $8.9 billion, up 31707.94% from the prior year.
- Common Equity for Q4 2025 stood at $8.9 billion, down from $9.2 billion in the prior quarter.
- The five-year high for Common Equity was $9.2 billion in Q4 2024, with the low at $7.8 billion in Q4 2021.
- Historically, Common Equity has averaged $8.4 billion across 5 years, with a median of $8.1 billion in 2022.
- Annual changes were most pronounced in 2021 — Common Equity soared 1539.99% — and 2025, when it retreated 3.76%.
- Grifols' Common Equity stood at $7.8 billion in 2021, then climbed by 3.73% to $8.1 billion in 2022, then decreased by 0.68% to $8.1 billion in 2023, then grew by 13.77% to $9.2 billion in 2024, then dropped by 3.76% to $8.9 billion in 2025.
- The last three Common Equity figures came in at $8.9 billion (Q4 2025), $9.2 billion (Q4 2024), and $8.1 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 23.49 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 31.20 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 81.19 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -6.61 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 45.93 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 9.19 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 23.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 90.40 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 20.10 Bn |
| 10 | Grifols | - | - | - | 8.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.85 Bn |
| Dec 31, 2024 | 9.20 Bn |
| Dec 31, 2023 | 8.08 Bn |
| Dec 31, 2022 | 8.14 Bn |
| Dec 31, 2021 | 7.85 Bn |
| Dec 31, 2020 | -544.88 Mn |
| Sep 30, 2020 | 8.30 Bn |
| Mar 31, 2020 | 7.96 Bn |
| Dec 31, 2019 | 7.58 Bn |
| Sep 30, 2019 | 5.89 Bn |
| Dec 31, 2018 | 5.36 Bn |
| Sep 30, 2018 | 4.82 Bn |
| Jun 30, 2018 | 4.74 Bn |
| Mar 31, 2018 | 5.99 Bn |
| Dec 31, 2017 | 4.28 Bn |
| Jun 30, 2017 | 3.94 Bn |
| Dec 31, 2016 | 4.03 Bn |
| Sep 30, 2016 | 3.94 Bn |
| Jun 30, 2016 | 3.86 Bn |
| Mar 31, 2016 | 3.64 Bn |